Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.52 |
| ▸ | AGXT | P21549 | 2/20 | 0.52 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 9/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL649272 | 0.88 | IDO1 (0.44) | IDO1AGXTTAAR1 | |
| SCHEMBL8781581 | 0.83 | IDO1 (0.54) | IDO1AGXTTRPA1MAOBAPP | |
| SCHEMBL21587147 | 0.83 | IDO1 (0.48) | IDO1AGXTLMNAKMT2ATRPA1 | |
| SCHEMBL7284728 | 0.83 | IDO1 (0.48) | IDO1AGXTTRPA1MAOBAPP | |
| SCHEMBL2308449 | 0.83 | IDO1 (0.48) | IDO1AGXTKMT2ATRPA1MAOB | |
| SCHEMBL1337524 | 0.81 | IDO1 (0.41) | IDO1AGXTMAOB | |
| SCHEMBL23634056 | 0.81 | IDO1 (0.47) | IDO1AGXTLMNATRPA1MAOB | |
| SCHEMBL19598855 | 0.79 | IDO1 (0.45) | IDO1AGXTLMNAKMT2ATRPA1 | |
| SCHEMBL5728580 | 0.79 | IDO1 (0.50) | IDO1AGXTTRPA1MAOBAPP | |
| SCHEMBL1927583 | 0.79 | IDO1 (0.50) | IDO1AGXTTRPA1MAOBAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230132298-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, LLC | 2023-04-27 | — | — | US | disclosed |
| US-11578087-B2 | Oxaborole esters and uses thereof | ANACOR PHARMACEUTICALS, INC. (US) | 2023-02-14 | — | — | US | disclosed |
| US-20230041761-A1 | SMALL MOLECULE MODULATORS OF SIGMA-1 AND SIGMA-2 RECEPTORS AND USES THEREOF | NORTHWESTERN UNIVERSITY | 2023-02-09 | — | — | US | disclosed |
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | PLIANT THERAPEUTICS, INC. | 2022-05-12 | — | — | US | disclosed |
| US-11208397-B2 | Small molecule antagonists of sumo related modification of CRMP2 and uses thereof | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2021-12-28 | — | — | US | disclosed |
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | NUVATION BIO INC (US) | 2021-09-23 | — | — | US | disclosed |
| WO-2021146629-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | NUVATION BIO INC. (US) | 2021-07-22 | — | — | WO | disclosed |
| US-11058676-B2 | Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof | PHARMAKEA, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| WO-2021136238-A1 | FUSED RING COMPOUND AND APPLICATION THEREOF | 武汉朗来科技发展有限公司 | 2021-07-08 | — | — | WO | disclosed |
| US-20210101916-A1 | OXABOROLE ESTERS AND USES THEREOF | ANACOR PHARMACEUTICALS, INC. | 2021-04-08 | — | — | US | disclosed |
| US-20120252027-A1 | Method For Rapidly Evaluating Performance Of Short Interfering RNA With Novel Chemical Modifications | BANK OF AMERICA, N.A. | 2012-10-04 | — | — | US | disclosed |
| US-20120252027-A1 | Method For Rapidly Evaluating Performance Of Short Interfering RNA With Novel Chemical Modifications | BANK OF AMERICA, N.A. | 2012-10-04 | — | — | US | disclosed |
| US-7935713-B2 | Glucagon receptor antagonist compounds, compositions containing such compounds and methods of use | MERCK SHARP & DOHME CORP. (US) | 2011-05-03 | — | — | US | disclosed |
| WO-2009101917-A1 | BICYCLOAMINE DERIVATIVE | EISAI R & D MANAGEMENT CO., LTD. (JP) | 2009-08-20 | — | — | WO | disclosed |
| US-20090118233-A1 | Heterocyclic compounds having inhibitory activity against HIV integrase | MURAI HITOSHI | 2009-05-07 | — | — | US | disclosed |
| US-20090118233-A1 | Heterocyclic compounds having inhibitory activity against HIV integrase | MURAI HITOSHI | 2009-05-07 | — | — | US | disclosed |
| US-20090105310-A1 | Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds and Methods of Use | MERCK SHARP & DOHME LLC | 2009-04-23 | — | — | US | disclosed |
| US-7358249-B2 | Heterocyclic compounds having inhibitory activity against HIV integrase | SHIONOGI & CO., LTD. (JP) | 2008-04-15 | — | — | US | disclosed |
| US-7358249-B2 | Heterocyclic compounds having inhibitory activity against HIV integrase | SHIONOGI & CO., LTD. (JP) | 2008-04-15 | — | — | US | disclosed |
| EP-1202628-B1 | NOVEL HYPOXANTHINE AND THIOHYPOXANTHINE COMPOUNDS | EURO CELTIQUE SA (LU) | 2004-10-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090118233-A1 | Heterocyclic compounds having inhibitory activity against HIV integrase | CYP3A7, CDK7, CYP2A7 | IDO1 81/4885AGXT 1806/4885LMNA 1842/4885 |
| US-20220144829-A1 | AMINO ACID COMPOUNDS AND METHODS OF USE | ITGB6, ITGA1, ITGAL | IDO1 1285/4885AGXT 328/4885LMNA 1922/4885 |
| US-20090105310-A1 | Glucagon Receptor Antagonist Compounds, Compositions Containing Such Compounds and Methods of Use | GCGR, GLP1R, GPR119 | IDO1 4014/4885AGXT 621/4885LMNA 2268/4885 |
| US-20230132298-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | IDO1 2671/4885AGXT 745/4885LMNA 2067/4885 |
| US-11058676-B2 | Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof | LOXL2, LOXL1, LOX | IDO1 360/4885AGXT 526/4885LMNA 137/4885 |
| US-11208397-B2 | Small molecule antagonists of sumo related modification of CRMP2 and uses thereof | SUMO2, SUMO1, SUMO3 | IDO1 3681/4885AGXT 4873/4885LMNA 2662/4885 |
| US-20210292285-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | ADORA2A, ADORA3, ADORA1 | IDO1 2160/4885AGXT 2973/4885LMNA 4458/4885 |
| US-20210101916-A1 | OXABOROLE ESTERS AND USES THEREOF | OXA1L, HSD17B12, OXER1 | IDO1 2671/4885AGXT 745/4885LMNA 2067/4885 |
| US-20120252027-A1 | Method For Rapidly Evaluating Performance Of Short Interfering RNA With Novel Chemical Modifications | NSUN2, NSUN3, SNRPE | IDO1 2887/4885AGXT 3081/4885LMNA 2808/4885 |
| US-11578087-B2 | Oxaborole esters and uses thereof | OXA1L, HSD17B12, OXER1 | IDO1 2671/4885AGXT 745/4885LMNA 2067/4885 |
| US-20230041761-A1 | SMALL MOLECULE MODULATORS OF SIGMA-1 AND SIGMA-2 RECEPTORS AND USES THEREOF | SIGMAR1, TMEM97, OPRM1 | IDO1 1044/4885AGXT 3829/4885LMNA 4760/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.